Humanized Anti-Gal-3 BP Antibody-Drug Conjugate

MP-1959 is the humanized version of the murine monoclonal antibody SP-2 which recognizes Gal-3 BP (also known as LGALS3BP, 90K or Mac-2 BP), is a glycoprotein secreted in large amounts by the majority of tumor cells, which plays an important role in cell-cell and cell-extracellular matrix adhesion and tumor invasion. In addition, Gal-3 BP functions as a pro-angiogenic factor through a dual mechanism, i.e by induction of tumor VEGF and stimulation of endothelial cell tubulogenesis, which is inhibited by MP-SP2/1959.

MediaPharma’s scientists have generated a non-internalizing anti-Gal-3 BP Antibody-Drug Conjugate (LGS-ADC). It consists of a humanized, engineered anti-Gal-3 BP monoclonal antibody (1959-sss) directly conjugated to highly potent maytansinoids (DM3 & DM4) via a disulfide bond to residual cysteine of the antibody light chain.  Administration of  LGS-ADC was effective in inducing a long lasting tumor shrinkage of tumor cell tumor cell lines and patient-derived tumor xenografts.

Indications in Oncology: cancers overexpressing Gal-3 BP, including those arising from breast, prostrate, ovary, pancreas, lung. melanoma, glioblastoma and neuroblastoma